Undercarboxylated Osteocalcin As a Biomarker of Subclinical Atherosclerosis in Non-dialysis Patients with Chronic Kidney Disease

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2015 Sep 19

PMID 26381729

Citations 12

Authors

Minfang Zhang

Zhaohui Ni

Wenyan Zhou

Jiaqi Qian

Affiliations

Soon will be listed here.

Abstract

Background: Studies in recent years have shown that undercarboxylated osteocalcin (uOC) not only maintains bone mineralization, but is also involved in the regulation of atherosclerosis. However, a correlation between uOC and carotid atherosclerosis in non-dialysis patients with chronic kidney disease (CKD) has not been investigated. A total of 240 non-dialysis patients with CKD were included in the study. For these patients, the median estimated glomerular filtration rate (eGFR) was 20.05 (12.43-49.32) ml/min/1.73m(2). Serum uOC levels were measured using enzyme-linked immunosorbent assay (ELISA). Carotid ultrasonography was performed to assess carotid atherosclerotic plaques and intima-media thickness (IMT) in an attempt to analyze the relationship between uOC level and carotid atherosclerosis.

Results: The uOC levels of non-dialysis patients with CKD were significantly lower than those of healthy controls [28.16 (21.40-45.85) ng/mL vs. 36.42 (28.05-49.28) ng/mL, P < 0.01]. The uOC levels gradually decreased as CKD progressed (P < 0.01). The uOC levels were significantly lower in patients with carotid plaques than in patients without carotid plaques [25.98 (20.14-31.35) ng/mL vs. 31.02 (25.86-36.40) ng/mL, P < 0.01]. uOC level showed significant negative correlation with IMT (r = -0.33, P < 0.01). Logistic regression analysis revealed that after adjustment for various confounding factors, decreased uOC levels were shown to indicate increased possibility of carotid atherosclerotic plaque development in non-dialysis patients with CKD (on every 1 SD decrease in the uOC level, odds ratio 1.70, 95 % confidence interval 1.24-2.98, P < 0.01). Multivariate stepwise regression analysis demonstrated that decreased uOC level (β = -0.163, P < 0.05) was an independent risk factor for increased carotid IMT in non-dialysis patients with CKD.

Conclusion: Serum uOC levels in non-dialysis patients with CKD are significantly lower than those in healthy individuals, and uOC is closely associated with subclinical atherosclerosis in CKD patients.

Citing Articles

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview.

Izzo C, Secondulfo C, Bilancio G, Visco V, Virtuoso N, Migliarino S Life (Basel). 2024; 14(3).

PMID: 38541742 PMC: 10971621. DOI: 10.3390/life14030418.

Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.

Fusaro M, Pereira L, Bover J J Clin Med. 2023; 12(19).

PMID: 37834950 PMC: 10573159. DOI: 10.3390/jcm12196306.

Osteocalcin-expressing endothelial progenitor cells and serum osteocalcin forms are independent biomarkers of coronary atherosclerotic disease severity in male and female patients.

Shahrour H, Al Fahom S, Al-Massarani G, AlSaadi A, Magni P J Endocrinol Invest. 2022; 45(6):1173-1180.

PMID: 35089541 PMC: 9098612. DOI: 10.1007/s40618-022-01744-3.

Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality.

Kaminska J, Stopinski M, Mucha K, Pac M, Golebiowski M, Niewczas M Int J Gen Med. 2021; 14:2413-2420.

PMID: 34135625 PMC: 8200134. DOI: 10.2147/IJGM.S302251.

Muscle-Bone Crosstalk in Chronic Kidney Disease: The Potential Modulatory Effects of Exercise.

Leal D, Ferreira A, Watson E, Wilund K, Viana J Calcif Tissue Int. 2021; 108(4):461-475.

PMID: 33388899 DOI: 10.1007/s00223-020-00782-4.

References

Singh S, Suresh M, Voleti B, Agrawal A . The connection between C-reactive protein and atherosclerosis. Ann Med. 2008; 40(2):110-20. PMC: 3364506. DOI: 10.1080/07853890701749225. View

Reyes-Garcia R, Rozas-Moreno P, Jimenez-Moleon J, Villoslada M, Garcia-Salcedo J, Santana-Morales S . Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. Diabetes Metab. 2011; 38(1):76-81. DOI: 10.1016/j.diabet.2011.07.008. View

Gossl M, Modder U, Atkinson E, Lerman A, Khosla S . Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol. 2008; 52(16):1314-25. PMC: 2613163. DOI: 10.1016/j.jacc.2008.07.019. View

Recio-Mayoral A, Banerjee D, Streather C, Kaski J . Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis. 2011; 216(2):446-51. DOI: 10.1016/j.atherosclerosis.2011.02.017. View

Im J, Yu B, Jeon J, Kim S . Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta. 2008; 396(1-2):66-9. DOI: 10.1016/j.cca.2008.07.001. View

Montalcini T, Emanuele V, Ceravolo R, Gorgone G, Sesti G, Perticone F . Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. Am J Cardiol. 2004; 94(2):266-9. DOI: 10.1016/j.amjcard.2004.03.083. View

Lee N, Sowa H, Hinoi E, Ferron M, Ahn J, Confavreux C . Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130(3):456-69. PMC: 2013746. DOI: 10.1016/j.cell.2007.05.047. View

Bini A, Mann K, Kudryk B, Schoen F . Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1999; 19(8):1852-61. DOI: 10.1161/01.atv.19.8.1852. View

Kapustin A, Shanahan C . Osteocalcin: a novel vascular metabolic and osteoinductive factor?. Arterioscler Thromb Vasc Biol. 2011; 31(10):2169-71. DOI: 10.1161/ATVBAHA.111.233601. View

10.

Zhang Y, Qi L, Gu W, Yan Q, Dai M, Shi J . Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults. Am J Cardiol. 2010; 106(10):1461-5. DOI: 10.1016/j.amjcard.2010.07.013. View

11.

Pittas A, Harris S, Eliades M, Stark P, Dawson-Hughes B . Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2008; 94(3):827-32. PMC: 2681283. DOI: 10.1210/jc.2008-1422. View

12.

Zyga S, Christopoulou G, Malliarou M . Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. J Ren Care. 2011; 37(1):12-5. DOI: 10.1111/j.1755-6686.2011.00201.x. View

13.

Ferron M, Hinoi E, Karsenty G, Ducy P . Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008; 105(13):5266-70. PMC: 2278202. DOI: 10.1073/pnas.0711119105. View

14.

Polgreen L, Jacobs Jr D, Nathan B, Steinberger J, Moran A, Sinaiko A . Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity (Silver Spring). 2012; 20(11):2194-201. PMC: 3483437. DOI: 10.1038/oby.2012.108. View

15.

Fujii H, Nakai K, Fukagawa M . Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial. 2011; 15(2):125-8. DOI: 10.1111/j.1744-9987.2010.00883.x. View

16.

Luo G, Ducy P, McKee M, Pinero G, Loyer E, Behringer R . Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386(6620):78-81. DOI: 10.1038/386078a0. View

17.

Stompor T, Krasniak A, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K . Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant. 2004; 20(2):404-12. DOI: 10.1093/ndt/gfh597. View

18.

Zuo L, Ma Y, Zhou Y, Wang M, Xu G, Wang H . Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis. 2005; 45(3):463-72. DOI: 10.1053/j.ajkd.2004.11.012. View

19.

Prats-Puig A, Osiniri I, Soriano-Rodriguez P, Carreras-Badosa G, Bunuel-Alvarez J, Vila-Pablos C . Undercarboxylated osteocalcin relates to cardiovascular risk markers in offspring of families with metabolic syndrome. Atherosclerosis. 2014; 233(1):272-7. DOI: 10.1016/j.atherosclerosis.2014.01.002. View

20.

Alfadda A, Masood A, Shaik S, Dekhil H, Goran M . Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 Diabetes. Int J Endocrinol. 2013; 2013:197519. PMC: 3638647. DOI: 10.1155/2013/197519. View